Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
UTOPIA Phase 3 Trial of UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC - Abhishek Srivastava
Abhishek Srivastava presents UTOPIA trial data, covering UGN-103, a reformulation of intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle-invasive ...
Aurea Molina Diaz discusses the PrInCIS-NIADY, a nationwide Spanish real-world study of adjuvant nivolumab in patients with high-risk PD-L1-positive muscle-invasive urothelial carcinoma following ...
Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...
Ronald Chen presents quality of life results from the AMBASSADOR trial, a randomized study of adjuvant pembrolizumab versus observation in high-risk urothelial carcinoma after radical surgery. Quality ...
The fourth episode in this podcast series features a discussion between the two principal investigators from the phase III EMBARK trial (NCT02319837). EMBARK showed that in patients with prostate ...
Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
CDK12 mutations occur in 2-7% of metastatic prostate cancers (mPCa) and are considered to be exclusively somatic. Here, we identified five patients with mPCa (ages 44-62) harboring germline CDK12 ...
The study aimed to evaluate whether continuing α-blocker therapy for one month after aquablation improves early clinical outcomes in patients undergoing surgery for benign prostatic obstruction (BPO).
To evaluate the financial impact of surgical modalities for benign prostatic hyperplasia (BPH) from the perspective of an NHS Trust. A retrospective analysis of patients undergoing Aquablation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results